Burnham & Co LLC Makes New Investment in Stryker Corporation $SYK

Burnham & Co LLC bought a new position in shares of Stryker Corporation (NYSE:SYK) in the second quarter, HoldingsChannel reports. The firm bought 12,107 shares of the medical technology company’s stock, valued at approximately $3,812,000. Stryker comprises about 3.1% of Burnham & Co LLC’s investment portfolio, making the stock its 11th largest position.

Several other institutional investors also recently bought and sold shares of SYK. Gables Capital Management Inc. purchased a new position in shares of Stryker in the second quarter valued at $25,000. Kilter Group LLC purchased a new stake in Stryker during the second quarter valued at $25,000. Godfrey Financial Associates Inc. bought a new position in Stryker during the fourth quarter valued at $26,000. Sankala Group LLC purchased a new stake in shares of Stryker during the 4th quarter valued at about $26,000. Finally, United Financial Planning Group LLC purchased a new stake in shares of Stryker during the 3rd quarter valued at about $27,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Stock Up 0.7%

NYSE:SYK opened at $329.86 on Friday. The company’s 50-day simple moving average is $326.99 and its 200-day simple moving average is $332.64. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86. The stock has a market capitalization of $126.52 billion, a P/E ratio of 34.18, a P/E/G ratio of 2.09 and a beta of 0.76.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same period in the prior year, the firm posted $3.13 earnings per share. The business’s quarterly revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio is currently 36.48%.

Insider Buying and Selling at Stryker

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Debra King sold 826 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the transaction, the insider owned 6,210 shares in the company, valued at $2,088,423. The trade was a 11.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 665,370 shares of company stock worth $216,238,501. 4.60% of the stock is owned by insiders.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here’s Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Needham & Company LLC dropped their target price on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a report on Friday, May 1st. Sanford C. Bernstein set a $410.00 price target on Stryker in a research report on Friday, May 1st. BTIG Research dropped their price objective on shares of Stryker from $371.00 to $358.00 and set a “buy” rating for the company in a research note on Friday, July 31st. UBS Group began coverage on shares of Stryker in a research note on Tuesday, July 28th. They issued a “buy” rating and a $400.00 target price on the stock. Finally, Leerink Partners lowered their target price on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a report on Friday, June 5th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Stryker presently has an average rating of “Moderate Buy” and a consensus target price of $386.28.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.